Key facts
- Carlsmed (NAS: CARL)’s last known valuation is $397.7M (Jul 2025).
- It has raised $209.6M; the latest was IPO ($100.5M) in Jul 2025.
- Notable investors include B Capital Group, U.S. Venture Partners.
- Status: Publicly Held.
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Carlsmed (NAS: CARL)
- ·The full record, as it builds
Funding rounds
No funding rounds for Carlsmed (NAS: CARL) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Carlsmed (NAS: CARL)
Carlsmed Inc is a commercial-stage medical technology company focused on developing AI-enabled personalized solutions for spine surgery. The company operates as a single operating and reportable segment engaged in the design, manufacture, and marketing of its Aprevo technology platform, which provides customized surgical planning and implants for lumbar and cervical spine fusion procedures, mainly sold to hospitals and ambulatory surgical centers.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2018
- Employees
- 127
- Website
- carlsmed.com/
- Ownership
- Publicly Held
Carlsmed (NAS: CARL) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Carlsmed (NAS: CARL) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Carlsmed (NAS: CARL) in its N-PORT filings yet. We sweep new filings monthly.